HK:1672 Stock Latest News
Company AnnouncementsAscletis to Present Preclinical Obesity Data at ObesityWeek 20267h ago1672
Company AnnouncementsAscletis’ Oral GLP-1 Drug Shows Strong Phase II Diabetes Data With Solid Safety Profile4d ago1672
Company AnnouncementsAscletis Submits FDA IND for New Oral Amylin Agonist to Treat Obesity1w ago1672
Company AnnouncementsAscletis Partner Sagimet Starts Pivotal U.S. Phase III Trial of Acne Drug Denifanstat1w ago1672
Company AnnouncementsAscletis touts positive preclinical data for once-weekly oral obesity peptide pipeline1w ago1672
Company AnnouncementsAscletis touts ultra-long-acting obesity candidate with strong preclinical weight-loss data1M ago1672Company AnnouncementsAscletis reports strong early U.S. trial data for oral psoriasis drug ASC501M ago1672
Company AnnouncementsAscletis Pharma Shares Added to Shanghai and Shenzhen-Hong Kong Stock Connect1M ago1672
Company AnnouncementsAscletis Deepens R&D Push as Loss Widens on Obesity Drug Pipeline2M ago1672- Company AnnouncementsAscletis Starts Global Phase III Trials of Oral GLP‑1 Drug ASC30 for Obesity2M ago1672
- Company AnnouncementsAscletis Widens Loss on R&D Surge as Obesity Drug Pipeline Advances2M ago1672
Company AnnouncementsAscletis Starts U.S. Phase I Trials for Ultra-Long-Acting Obesity Injections2M ago1672Company AnnouncementsAscletis launches global Phase III obesity trial and advances oral triple agonist portfolio3M ago1672
Company AnnouncementsAscletis Pharma Schedules Board Meeting to Review 2026 Interim Results and Dividend3M ago1672
Company AnnouncementsAscletis Advances Once-Monthly Obesity Drug ASC37 With Strong Preclinical Results3M ago1672
Company AnnouncementsAscletis Showcases Preclinical Obesity Drug with Superior Weight-Loss Data at EASD 20263M ago1672
Company AnnouncementsAscletis Advances First-in-Class Oral GLP/GIP Combo for Obesity3M ago1672
Company AnnouncementsAscletis files U.S. INDs for next‑generation monthly obesity injections3M ago1672
Company AnnouncementsAscletis Pharma Launches HK$300 Million Share Buyback Under Mandate4M ago1672Company AnnouncementsAscletis Pharma Wins Shareholder Backing for All AGM Resolutions and Capital Mandates4M ago1672
Company AnnouncementsAscletis Wins FDA Green Light for Monthly Obesity Drug ASC35 Phase I Trial4M ago1672